{"id":628,"date":"2024-03-06T23:01:46","date_gmt":"2024-03-06T23:01:46","guid":{"rendered":"https:\/\/montdorex.com\/?page_id=628"},"modified":"2024-04-30T03:42:57","modified_gmt":"2024-04-30T03:42:57","slug":"nouvelles","status":"publish","type":"page","link":"https:\/\/montdorex.com\/fr\/nouvelles\/","title":{"rendered":"Nouvelles"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][info_banner_vc google_fonts=\u00a0\u00bbfont_family:Abril%20Fatface%3Aregular|font_style:400%20regular%3A400%3Anormal\u00a0\u00bb image_id=\u00a0\u00bb622&Prime;][\/info_banner_vc]<div class=\"mgt-header-block clearfix text-left text-custom wpb_content_element  mgt-header-block-style-1 mgt-header-block-fontsize-regular mgt-header-texttransform-none mgt-header-block-76979538 \"><h2 class=\"mgt-header-block-title text-font-weight-100\">Communiqu\u00e9s<\/h2><\/div><style scoped='scoped'>.mgt-header-block-76979538.mgt-header-block .mgt-header-block-title {color: #2a3390!important;}<\/style>[vc_tta_accordion][vc_tta_section title=\u00a0\u00bb07.03.2024&Prime; tab_id=\u00a0\u00bbPRno1&Prime;][vc_column_text]<span style=\"color: #0c7e40; font-size: 18px;\"><strong>MONTDOREX ANNONCE QUE SON R\u00c9SUM\u00c9 DE PR\u00c9SENTATION AU CONGR\u00c8S ANNUEL 2024 DE L\u2019AACR A \u00c9T\u00c9 ACCEPT\u00c9<\/strong><\/span><\/p>\n<p><span style=\"color: #000000; font-size: 18px;\"><em>Le r\u00e9sum\u00e9 s\u00e9lectionn\u00e9 inclut des donn\u00e9es pr\u00e9cliniques sur le MTDX203, un inhibiteur de l\u2019endo-exonucl\u00e9ase exclusif et de nouvelle classe aux propri\u00e9t\u00e9s anti-canc\u00e9reuses. <\/em><\/span><\/p>\n<p><span style=\"color: #000000; font-size: 16px;\"><strong>Montr\u00e9al, Canada, le 7 mars 2024 (BusinessWire)<\/strong>&#8211; Montdorex Inc. (\u00ab Montdorex \u00bb ou \u00ab la Soci\u00e9t\u00e9 \u00bb), une soci\u00e9t\u00e9 priv\u00e9e de m\u00e9decine de pr\u00e9cision, annonce aujourd\u2019hui que Terry Chow, Ph.D., fondateur et chef de la direction, pr\u00e9sentera des \u00e9l\u00e9ments d\u2019int\u00e9r\u00eat sur la pertinence de l\u2019inhibition de l\u2019enzyme endo-exonucl\u00e9ase (EE) lors d\u2019une pr\u00e9sentation d\u2019affiche au congr\u00e8s annuel de l\u2019American Association for Cancer Research (AACR), qui se tiendra \u00e0 San Diego (Californie) du 5 au 10 avril 2024.<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 16px;\">L\u2019enzyme endo-exonucl\u00e9ase joue un r\u00f4le cl\u00e9 dans les m\u00e9canismes de r\u00e9paration des dommages \u00e0 l\u2019ADN, mais est \u00e9galement surexprim\u00e9e dans les tumeurs canc\u00e9reuses. Lors d\u2019une \u00e9tude de preuve-de-concept, Montdorex a montr\u00e9 que les tumeurs dans lesquelles l\u2019expression de l\u2019EE \u00e9tait accrue r\u00e9pondaient le mieux \u00e0 l\u2019action de la pentamidine, un inhibiteur de l\u2019endo-exonucl\u00e9ase. La Soci\u00e9t\u00e9 a \u00e9galement identifi\u00e9 des analogues de mono- et di-amidine de la pentamidine dont l\u2019efficacit\u00e9 s\u2019est av\u00e9r\u00e9e sup\u00e9rieure \u00e0 celle du m\u00e9dicament initial lors d\u2019\u00e9tudes <em>in vitro<\/em> et <em>in vivo<\/em>.<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 16px;\">\u00ab Notre compos\u00e9 principal, le MTDX203, a montr\u00e9 une activit\u00e9 anti-canc\u00e9reuse plus grande que la pentamidine lors d\u2019\u00e9tudes animales pr\u00e9cliniques, ainsi qu\u2019un niveau d\u2019innocuit\u00e9 plus \u00e9lev\u00e9 \u00bb, a d\u00e9clar\u00e9 Terry Chow de Montdorex. \u00ab Je suis impatient de pr\u00e9senter nos r\u00e9sultats d\u00e9taill\u00e9s \u00e0 la communaut\u00e9 scientifique et financi\u00e8re qui sera pr\u00e9sente au congr\u00e8s annuel 2024 de l\u2019AACR \u00bb.<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 16px;\">Les d\u00e9tails relatifs \u00e0 la pr\u00e9sentation d\u2019affiche lors du congr\u00e8s de l\u2019AACR sont les suivants : <\/span><\/p>\n<p><span style=\"color: #000000; font-size: 16px;\"><strong>Pr\u00e9sentation d\u2019affiche no 5604 : La modulation de la r\u00e9paration de l\u2019ADN par l\u2019inhibition de l\u2019endo-exonucl\u00e9ase : un nouveau paradigme th\u00e9rapeutique en oncologie<\/strong><span style=\"color: #000000; font-size: 16px;\"><a href=\"https:\/\/www.abstractsonline.com\/pp8\/#!\/20272\/presentation\/7490\" target=\"_blank\" rel=\"noopener\">[lien vers le r\u00e9sum\u00e9 publi\u00e9 en anglais]<\/a><\/span><\/span><\/p>\n<p><span style=\"color: #000000; font-size: 16px;\">Type de session : Biologie mol\u00e9culaire \/ cellulaire et g\u00e9n\u00e9tique<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 16px;\">Titre de la session : ADN : dommages et r\u00e9paration 2<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 16px;\">Date et heure : Mardi 9 avril 2024 de 13 h 30 \u00e0 17 h (HP)<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 16px;\">Lieu : Section d\u2019affiches no 14, tableau no 2<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 16px;\"><strong>\u00c0 propos de Montdorex<\/strong><\/span><\/p>\n<p><span style=\"color: #000000; font-size: 16px;\">Bas\u00e9e \u00e0 Montr\u00e9al (Canada), Montdorex Inc. est une compagnie priv\u00e9e de m\u00e9decine de pr\u00e9cision qui cible l\u2019enzyme endo-exonucl\u00e9ase (EE) impliqu\u00e9e dans la croissance de tumeurs canc\u00e9reuses et dans des processus inflammatoires. La Soci\u00e9t\u00e9 d\u00e9veloppe des mono-amidines et di-amidines exclusifs pour inhiber l\u2019EE afin de moduler la r\u00e9paration d\u2019ADN en oncologie, ainsi que des analogues de di-amidine non cytotoxiques en vue d\u2019applications anti-inflammatoires, telles que des conditions gastro-intestinales et des maladies h\u00e9patiques.<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 16px;\"><strong>Contact<\/strong><\/span><\/p>\n<p><span style=\"color: #000000; font-size: 16px;\">Terry Y-K Chow, Ph.D.<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 16px;\">Fondateur et chef de la direction<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 16px;\"><a href=\"mailto:tchow@montdorex.com\">tchow@montdorex.com<\/a><\/span>[\/vc_column_text][\/vc_tta_section][\/vc_tta_accordion][vc_single_image image=\u00a0\u00bb741&Prime; img_size=\u00a0\u00bbfull\u00a0\u00bb onclick=\u00a0\u00bbcustom_link\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb link=\u00a0\u00bbhttp:\/\/www.montdorex.com\/fr\/publications\u00a0\u00bb][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][info_banner_vc google_fonts=\u00a0\u00bbfont_family:Abril%20Fatface%3Aregular|font_style:400%20regular%3A400%3Anormal\u00a0\u00bb image_id=\u00a0\u00bb622&Prime;][\/info_banner_vc][vc_tta_accordion][vc_tta_section title=\u00a0\u00bb07.03.2024&Prime; tab_id=\u00a0\u00bbPRno1&Prime;][vc_column_text]MONTDOREX ANNONCE QUE SON R\u00c9SUM\u00c9 DE PR\u00c9SENTATION AU CONGR\u00c8S ANNUEL 2024 DE L\u2019AACR A \u00c9T\u00c9 ACCEPT\u00c9 Le r\u00e9sum\u00e9 s\u00e9lectionn\u00e9 inclut des donn\u00e9es pr\u00e9cliniques sur le MTDX203, &#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"template-fullwidth.php","meta":{"footnotes":""},"_links":{"self":[{"href":"https:\/\/montdorex.com\/fr\/wp-json\/wp\/v2\/pages\/628"}],"collection":[{"href":"https:\/\/montdorex.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/montdorex.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/montdorex.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/montdorex.com\/fr\/wp-json\/wp\/v2\/comments?post=628"}],"version-history":[{"count":13,"href":"https:\/\/montdorex.com\/fr\/wp-json\/wp\/v2\/pages\/628\/revisions"}],"predecessor-version":[{"id":746,"href":"https:\/\/montdorex.com\/fr\/wp-json\/wp\/v2\/pages\/628\/revisions\/746"}],"wp:attachment":[{"href":"https:\/\/montdorex.com\/fr\/wp-json\/wp\/v2\/media?parent=628"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}